NCT07752511
Anticipated Stigma, Illness Identity, and Quality of Life in Male Hypogonadism
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
Notable Recruitment opened Show 4 more changesShow less
- Eligibility criteria expanded, about 18 words
- Start date changed from estimate of Oct 1, 2026 to Oct 20, 2026
- Secondary endpoints: details revised at 1 of 2 entries
- Site details revised at 2 of 2 sites
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Chronic Illness Anticipated Stigma Scale (CIASS) Score
Timeframe: Baseline (Single session, day 1)
Brief Illness Perception Questionnaire (Brief IPQ) Score
Timeframe: Baseline (Single session, day 1)
Secondary (2)
Aging Males' Symptoms (AMS) Scale Score
Hospital Anxiety and Depression Scale (HADS) Score
Arms and interventions
Hypogonadism Group (Case)
Male patients aged 18 years or older with biochemically confirmed hypogonadism (total testosterone \< 300 ng/dL with at least one clinical symptom) undergoing regular follow-up in the endocrinology clinic.
Control Group (Other Chronic Endocrine Diseases)
Male patients aged 18 years or older diagnosed with diabetes mellitus, hypertension, or hypothyroidism without hypogonadism (total testosterone ≥ 300 ng/dL), matched by age (±5 years) to the case group and under regular follow-up in the same endocrinology clinic.
Sites
2 sites in 1 country